| 0.746 0.019 (2.59%) | 12-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 0.97 | 1-year : | 1.09 |
| Resists | First : | 0.83 | Second : | 0.93 |
| Pivot price | 0.77  |
|||
| Supports | First : | 0.67 | Second : | 0.55 |
| MAs | MA(5) : | 0.74 |
MA(20) : | 0.77 |
| MA(100) : | 0.93 |
MA(250) : | 2.3 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 27.9 |
D(3) : | 31.4 |
| RSI | RSI(14): 41.7 |
|||
| 52-week | High : | 5.65 | Low : | 0.67 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ AWH ] has closed above bottom band by 33.2%. Bollinger Bands are 32.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.76 - 0.77 | 0.77 - 0.77 |
| Low: | 0.69 - 0.7 | 0.7 - 0.7 |
| Close: | 0.74 - 0.75 | 0.75 - 0.76 |
Aspira Women's Health Inc., together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company provides OVA1, OVERA, and OVA1plus to detect risk of ovarian malignancy in women with adnexal masses. It also offers ASPiRA GenetiX, a genetic test for the risk of gynecologic cancer. In addition, the company operates Aspira Synergy, a testing platform and cloud service for decentralized access of protein biomarker and hereditary genetic testing; and owns and operates ASPiRA LABS, a lab that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. Further, its pipeline products include OVAWatch, EndoCheck, and OVAInherit. The company serves physicians, physician office laboratories, and national and regional laboratories. It has a collaborative research agreement with Baylor Genetics; an agreement with Harvard Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University Lodz to evaluate the microRNA technology in combination with Aspira technologies for the development of an early detection test for ovarian cancer; and a strategic alliance with Quest Diagnostics, Incorporated. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was incorporated in 1993 and is headquartered in Austin, Texas.
Wed, 11 Dec 2024
Aspira Women's Health's SWOT analysis: stock faces growth potential amid financial hurdles - Investing.com Australia
Tue, 03 Dec 2024
Aspira Women's Health Successfully Reaches the First Milestone of the ARPA-H $10 Million Award - The Manila Times
Tue, 03 Dec 2024
Aspira Women's Health Secures $2M ARPA-H Grant for AI-Powered Endometriosis Test - StockTitan
Tue, 19 Nov 2024
Aspira: Q3 Earnings Snapshot - San Francisco Chronicle
Fri, 15 Nov 2024
Aspira Womens Health Inc (AWH) Q3 2024 Earnings Call Highlights: Strategic Wins Amidst Market ... - Yahoo Finance
Fri, 15 Nov 2024
Aspira Women’s Health Inc. (NASDAQ:AWH) Q3 2024 Earnings Call Transcript - Insider Monkey
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 17 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 30.9 (%) |
| Held by Institutions | 13.8 (%) |
| Shares Short | 538 (K) |
| Shares Short P.Month | 443 (K) |
| EPS | -1.15 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.22 |
| Profit Margin | -178.9 % |
| Operating Margin | -181.4 % |
| Return on Assets (ttm) | -185.8 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -2.8 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.53 |
| EBITDA (p.s.) | -1.04 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -15 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | -0.65 |
| PEG Ratio | 0 |
| Price to Book value | -3.4 |
| Price to Sales | 1.39 |
| Price to Cash Flow | -0.84 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|